nodes	percent_of_prediction	percent_of_DWPC	metapath
Metipranolol—Photophobia—Thiotepa—sarcoma	0.0278	0.0278	CcSEcCtD
Metipranolol—Lacrimation—Epirubicin—sarcoma	0.0203	0.0203	CcSEcCtD
Metipranolol—Lacrimation—Doxorubicin—sarcoma	0.0188	0.0188	CcSEcCtD
Metipranolol—Conjunctivitis—Thiotepa—sarcoma	0.0161	0.0161	CcSEcCtD
Metipranolol—Epistaxis—Thiotepa—sarcoma	0.0156	0.0156	CcSEcCtD
Metipranolol—Acute coronary syndrome—Vincristine—sarcoma	0.0145	0.0145	CcSEcCtD
Metipranolol—Myocardial infarction—Vincristine—sarcoma	0.0144	0.0144	CcSEcCtD
Metipranolol—Acute coronary syndrome—Mitoxantrone—sarcoma	0.0141	0.0141	CcSEcCtD
Metipranolol—Myocardial infarction—Mitoxantrone—sarcoma	0.014	0.014	CcSEcCtD
Metipranolol—Conjunctivitis—Mitoxantrone—sarcoma	0.0139	0.0139	CcSEcCtD
Metipranolol—Bradycardia—Mitoxantrone—sarcoma	0.0131	0.0131	CcSEcCtD
Metipranolol—Lacrimation increased—Epirubicin—sarcoma	0.0129	0.0129	CcSEcCtD
Metipranolol—Rhinitis—Mitoxantrone—sarcoma	0.0129	0.0129	CcSEcCtD
Metipranolol—Tension—Thiotepa—sarcoma	0.0127	0.0127	CcSEcCtD
Metipranolol—Nervousness—Thiotepa—sarcoma	0.0126	0.0126	CcSEcCtD
Metipranolol—Vision blurred—Thiotepa—sarcoma	0.0122	0.0122	CcSEcCtD
Metipranolol—Lacrimation increased—Doxorubicin—sarcoma	0.012	0.012	CcSEcCtD
Metipranolol—Acute coronary syndrome—Etoposide—sarcoma	0.0117	0.0117	CcSEcCtD
Metipranolol—Myocardial infarction—Etoposide—sarcoma	0.0117	0.0117	CcSEcCtD
Metipranolol—Cough—Thiotepa—sarcoma	0.0113	0.0113	CcSEcCtD
Metipranolol—Hypertension—Thiotepa—sarcoma	0.0112	0.0112	CcSEcCtD
Metipranolol—Myalgia—Thiotepa—sarcoma	0.011	0.011	CcSEcCtD
Metipranolol—Anxiety—Thiotepa—sarcoma	0.011	0.011	CcSEcCtD
Metipranolol—Myalgia—Dactinomycin—sarcoma	0.0109	0.0109	CcSEcCtD
Metipranolol—Discomfort—Dactinomycin—sarcoma	0.0108	0.0108	CcSEcCtD
Metipranolol—Vision blurred—Mitoxantrone—sarcoma	0.0105	0.0105	CcSEcCtD
Metipranolol—Oedema—Dactinomycin—sarcoma	0.0105	0.0105	CcSEcCtD
Metipranolol—Abnormal vision—Epirubicin—sarcoma	0.0104	0.0104	CcSEcCtD
Metipranolol—Hypertension—Vincristine—sarcoma	0.00991	0.00991	CcSEcCtD
Metipranolol—Myalgia—Vincristine—sarcoma	0.00978	0.00978	CcSEcCtD
Metipranolol—Cough—Mitoxantrone—sarcoma	0.00976	0.00976	CcSEcCtD
Metipranolol—Hypertension—Mitoxantrone—sarcoma	0.00965	0.00965	CcSEcCtD
Metipranolol—Musculoskeletal discomfort—Thiotepa—sarcoma	0.00963	0.00963	CcSEcCtD
Metipranolol—Abnormal vision—Doxorubicin—sarcoma	0.00962	0.00962	CcSEcCtD
Metipranolol—Musculoskeletal discomfort—Dactinomycin—sarcoma	0.00956	0.00956	CcSEcCtD
Metipranolol—Myalgia—Mitoxantrone—sarcoma	0.00952	0.00952	CcSEcCtD
Metipranolol—Anxiety—Mitoxantrone—sarcoma	0.00949	0.00949	CcSEcCtD
Metipranolol—Discomfort—Mitoxantrone—sarcoma	0.00941	0.00941	CcSEcCtD
Metipranolol—Somnolence—Thiotepa—sarcoma	0.00939	0.00939	CcSEcCtD
Metipranolol—Oedema—Vincristine—sarcoma	0.00937	0.00937	CcSEcCtD
Metipranolol—Oedema—Mitoxantrone—sarcoma	0.00913	0.00913	CcSEcCtD
Metipranolol—Musculoskeletal discomfort—Vincristine—sarcoma	0.00854	0.00854	CcSEcCtD
Metipranolol—Musculoskeletal discomfort—Mitoxantrone—sarcoma	0.00831	0.00831	CcSEcCtD
Metipranolol—Dyspnoea—Mitoxantrone—sarcoma	0.00814	0.00814	CcSEcCtD
Metipranolol—Cough—Etoposide—sarcoma	0.00812	0.00812	CcSEcCtD
Metipranolol—Somnolence—Mitoxantrone—sarcoma	0.00811	0.00811	CcSEcCtD
Metipranolol—Hypertension—Etoposide—sarcoma	0.00803	0.00803	CcSEcCtD
Metipranolol—Discomfort—Etoposide—sarcoma	0.00782	0.00782	CcSEcCtD
Metipranolol—Hypersensitivity—Thiotepa—sarcoma	0.00779	0.00779	CcSEcCtD
Metipranolol—Hypersensitivity—Dactinomycin—sarcoma	0.00773	0.00773	CcSEcCtD
Metipranolol—Asthenia—Thiotepa—sarcoma	0.00758	0.00758	CcSEcCtD
Metipranolol—Asthenia—Dactinomycin—sarcoma	0.00753	0.00753	CcSEcCtD
Metipranolol—Angina pectoris—Epirubicin—sarcoma	0.00729	0.00729	CcSEcCtD
Metipranolol—Bronchitis—Epirubicin—sarcoma	0.0072	0.0072	CcSEcCtD
Metipranolol—Dizziness—Thiotepa—sarcoma	0.00699	0.00699	CcSEcCtD
Metipranolol—Hypersensitivity—Vincristine—sarcoma	0.0069	0.0069	CcSEcCtD
Metipranolol—Dyspnoea—Etoposide—sarcoma	0.00677	0.00677	CcSEcCtD
Metipranolol—Somnolence—Etoposide—sarcoma	0.00675	0.00675	CcSEcCtD
Metipranolol—Angina pectoris—Doxorubicin—sarcoma	0.00674	0.00674	CcSEcCtD
Metipranolol—Hypersensitivity—Mitoxantrone—sarcoma	0.00672	0.00672	CcSEcCtD
Metipranolol—Asthenia—Vincristine—sarcoma	0.00672	0.00672	CcSEcCtD
Metipranolol—Rash—Thiotepa—sarcoma	0.00666	0.00666	CcSEcCtD
Metipranolol—Bronchitis—Doxorubicin—sarcoma	0.00666	0.00666	CcSEcCtD
Metipranolol—Dermatitis—Thiotepa—sarcoma	0.00666	0.00666	CcSEcCtD
Metipranolol—Headache—Thiotepa—sarcoma	0.00662	0.00662	CcSEcCtD
Metipranolol—Rash—Dactinomycin—sarcoma	0.00661	0.00661	CcSEcCtD
Metipranolol—Asthenia—Mitoxantrone—sarcoma	0.00655	0.00655	CcSEcCtD
Metipranolol—Conjunctivitis—Epirubicin—sarcoma	0.00649	0.00649	CcSEcCtD
Metipranolol—Epistaxis—Epirubicin—sarcoma	0.00629	0.00629	CcSEcCtD
Metipranolol—Nausea—Thiotepa—sarcoma	0.00628	0.00628	CcSEcCtD
Metipranolol—Nausea—Dactinomycin—sarcoma	0.00623	0.00623	CcSEcCtD
Metipranolol—Dizziness—Vincristine—sarcoma	0.0062	0.0062	CcSEcCtD
Metipranolol—Bradycardia—Epirubicin—sarcoma	0.0061	0.0061	CcSEcCtD
Metipranolol—Rhinitis—Epirubicin—sarcoma	0.006	0.006	CcSEcCtD
Metipranolol—Conjunctivitis—Doxorubicin—sarcoma	0.006	0.006	CcSEcCtD
Metipranolol—Rash—Vincristine—sarcoma	0.00591	0.00591	CcSEcCtD
Metipranolol—Dermatitis—Vincristine—sarcoma	0.0059	0.0059	CcSEcCtD
Metipranolol—Headache—Vincristine—sarcoma	0.00587	0.00587	CcSEcCtD
Metipranolol—Epistaxis—Doxorubicin—sarcoma	0.00582	0.00582	CcSEcCtD
Metipranolol—Visual impairment—Epirubicin—sarcoma	0.00577	0.00577	CcSEcCtD
Metipranolol—Rash—Mitoxantrone—sarcoma	0.00575	0.00575	CcSEcCtD
Metipranolol—Dermatitis—Mitoxantrone—sarcoma	0.00575	0.00575	CcSEcCtD
Metipranolol—Headache—Mitoxantrone—sarcoma	0.00572	0.00572	CcSEcCtD
Metipranolol—Bradycardia—Doxorubicin—sarcoma	0.00564	0.00564	CcSEcCtD
Metipranolol—Hypersensitivity—Etoposide—sarcoma	0.00559	0.00559	CcSEcCtD
Metipranolol—Nausea—Vincristine—sarcoma	0.00557	0.00557	CcSEcCtD
Metipranolol—Rhinitis—Doxorubicin—sarcoma	0.00556	0.00556	CcSEcCtD
Metipranolol—Asthenia—Etoposide—sarcoma	0.00545	0.00545	CcSEcCtD
Metipranolol—Nausea—Mitoxantrone—sarcoma	0.00542	0.00542	CcSEcCtD
Metipranolol—Visual impairment—Doxorubicin—sarcoma	0.00534	0.00534	CcSEcCtD
Metipranolol—Tension—Epirubicin—sarcoma	0.00512	0.00512	CcSEcCtD
Metipranolol—Nervousness—Epirubicin—sarcoma	0.00506	0.00506	CcSEcCtD
Metipranolol—Dizziness—Etoposide—sarcoma	0.00502	0.00502	CcSEcCtD
Metipranolol—Vision blurred—Epirubicin—sarcoma	0.00491	0.00491	CcSEcCtD
Metipranolol—Rash—Etoposide—sarcoma	0.00479	0.00479	CcSEcCtD
Metipranolol—Dermatitis—Etoposide—sarcoma	0.00478	0.00478	CcSEcCtD
Metipranolol—Headache—Etoposide—sarcoma	0.00476	0.00476	CcSEcCtD
Metipranolol—Tension—Doxorubicin—sarcoma	0.00473	0.00473	CcSEcCtD
Metipranolol—Nervousness—Doxorubicin—sarcoma	0.00469	0.00469	CcSEcCtD
Metipranolol—Palpitations—Epirubicin—sarcoma	0.00461	0.00461	CcSEcCtD
Metipranolol—Cough—Epirubicin—sarcoma	0.00455	0.00455	CcSEcCtD
Metipranolol—Vision blurred—Doxorubicin—sarcoma	0.00455	0.00455	CcSEcCtD
Metipranolol—Nausea—Etoposide—sarcoma	0.00451	0.00451	CcSEcCtD
Metipranolol—Hypertension—Epirubicin—sarcoma	0.0045	0.0045	CcSEcCtD
Metipranolol—Myalgia—Epirubicin—sarcoma	0.00444	0.00444	CcSEcCtD
Metipranolol—Anxiety—Epirubicin—sarcoma	0.00442	0.00442	CcSEcCtD
Metipranolol—Discomfort—Epirubicin—sarcoma	0.00439	0.00439	CcSEcCtD
Metipranolol—Palpitations—Doxorubicin—sarcoma	0.00426	0.00426	CcSEcCtD
Metipranolol—Oedema—Epirubicin—sarcoma	0.00426	0.00426	CcSEcCtD
Metipranolol—Cough—Doxorubicin—sarcoma	0.00421	0.00421	CcSEcCtD
Metipranolol—Hypertension—Doxorubicin—sarcoma	0.00416	0.00416	CcSEcCtD
Metipranolol—Myalgia—Doxorubicin—sarcoma	0.00411	0.00411	CcSEcCtD
Metipranolol—Anxiety—Doxorubicin—sarcoma	0.00409	0.00409	CcSEcCtD
Metipranolol—Discomfort—Doxorubicin—sarcoma	0.00406	0.00406	CcSEcCtD
Metipranolol—Oedema—Doxorubicin—sarcoma	0.00394	0.00394	CcSEcCtD
Metipranolol—Musculoskeletal discomfort—Epirubicin—sarcoma	0.00388	0.00388	CcSEcCtD
Metipranolol—Dyspnoea—Epirubicin—sarcoma	0.00379	0.00379	CcSEcCtD
Metipranolol—Somnolence—Epirubicin—sarcoma	0.00378	0.00378	CcSEcCtD
Metipranolol—Musculoskeletal discomfort—Doxorubicin—sarcoma	0.00359	0.00359	CcSEcCtD
Metipranolol—Dyspnoea—Doxorubicin—sarcoma	0.00351	0.00351	CcSEcCtD
Metipranolol—Somnolence—Doxorubicin—sarcoma	0.0035	0.0035	CcSEcCtD
Metipranolol—Hypersensitivity—Epirubicin—sarcoma	0.00313	0.00313	CcSEcCtD
Metipranolol—Asthenia—Epirubicin—sarcoma	0.00305	0.00305	CcSEcCtD
Metipranolol—Hypersensitivity—Doxorubicin—sarcoma	0.0029	0.0029	CcSEcCtD
Metipranolol—Asthenia—Doxorubicin—sarcoma	0.00282	0.00282	CcSEcCtD
Metipranolol—Dizziness—Epirubicin—sarcoma	0.00281	0.00281	CcSEcCtD
Metipranolol—Rash—Epirubicin—sarcoma	0.00268	0.00268	CcSEcCtD
Metipranolol—Dermatitis—Epirubicin—sarcoma	0.00268	0.00268	CcSEcCtD
Metipranolol—Headache—Epirubicin—sarcoma	0.00267	0.00267	CcSEcCtD
Metipranolol—Dizziness—Doxorubicin—sarcoma	0.0026	0.0026	CcSEcCtD
Metipranolol—Nausea—Epirubicin—sarcoma	0.00253	0.00253	CcSEcCtD
Metipranolol—Rash—Doxorubicin—sarcoma	0.00248	0.00248	CcSEcCtD
Metipranolol—Dermatitis—Doxorubicin—sarcoma	0.00248	0.00248	CcSEcCtD
Metipranolol—Headache—Doxorubicin—sarcoma	0.00247	0.00247	CcSEcCtD
Metipranolol—Nausea—Doxorubicin—sarcoma	0.00234	0.00234	CcSEcCtD
